Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing

Leukemia

Volumn 25, Issue 2, 2011, Pages 313-320

  Zaliova, M ^a   Madzo, J ^a   Cario, G ^b   Trka, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

acute lymphoblastic leukemia; childhood leukemia; fusion gene; RNAi; TEL AML1

Indexed keywords

HYBRID PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; TEL AML1 FUSION PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA INTERFERENCE;

EID: 79751526720     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.277     Document Type: Article

References (37)

1. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 2005; 15: 162-174.
2. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene 2000; 245: 223-235. (Pubitemid 30136427)
3. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffe M, Jonveaux P et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86: 4263-4269.
4. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-1989. (Pubitemid 26023779)
5. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A et al. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996; 16: 1349-1355. (Pubitemid 26095605)
6. Morrow M, Samanta A, Kioussis D, Brady HJ, Williams O. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene, 2007, 26, 4404-4414. (Pubitemid 47014465)
7. Fears S, Gavin M, Zhang DE, Hetherington C, Ben-David Y, Rowley JD et al. Functional characterization of ETV6 and ETV6/ CBFA2 in the regulation of the MCSFR proximal promoter. Proc Natl Acad Sci USA 1997; 94: 1949-1954. (Pubitemid 27113942)
8. Starkova J, Madzo J, Cario G, Kalina T, Ford A, Zaliova M et al. The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells. Clin Cancer Res 2007; 13: 1726-1735. (Pubitemid 46952938)
9. Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene 1999; 18: 1015-1022. (Pubitemid 29086278)
10. Andreasson P, Schwaller J, Anastasiadou E, Aster J, Gilliland DG. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet 2001; 130: 93-104. (Pubitemid 33033225)
11. Fischer M, Schwieger M, Horn S, Niebuhr B, Ford A, Roscher S et al. Defining the oncogenic function of the TEL/AML1 (ETV6/ RUNX1) fusion protein in a mouse model. Oncogene, 2005, 24, 7579-7591. (Pubitemid 41638032)
12. Morrow M, Horton S, Kioussis D, Brady HJ, Williams O. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood, 2004, 103, 3890-3896. (Pubitemid 38596310)
13. Tsuzuki S, Seto M, Greaves M, Enver T. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci USA 2004; 101: 8443-8448. (Pubitemid 38736594)
14. Kim DH, Moldwin RL, Vignon C, Bohlander SK, Suto Y, Giordano L et al. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood 1996; 88: 785-794. (Pubitemid 26333296)
15. Diakos C, Krapf G, Gerner C, Inthal A, Lemberger C, Ban J et al. RNAi-mediated silencing of TEL/AML1 reveals a heat-shock protein-and survivin-dependent mechanism for survival. Blood 2007; 109: 2607-2610. (Pubitemid 46425909)
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159. (Pubitemid 17064313)
17. Gabert J, Beillard E, Van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357. (Pubitemid 38072573)
18. Madzo J, Zuna J, Muzikova K, Kalinova M, Krejci O, Hrusak O et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer 2003; 97: 105-113. (Pubitemid 36033869)
19. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International 2004; 11: 36-42.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121. (Pubitemid 32397092)
21. Lou J, Cao W, Bernardin F, Ayyanathan K, Rauscher IF, Friedman AD. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominantnegative CBF -a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene 2000; 19: 2695-2703. (Pubitemid 30326419)
22. Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR et al. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem 2000; 275: 3438-3445. (Pubitemid 30083051)
23. Rangatia J, Bonnet D. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 2006; 20: 68-76.
24. Thomas M, Gessner A, Vornlocher HP, Hadwiger P, Greil J, Heidenreich O. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 2005; 106: 3559-3566. (Pubitemid 41609194)
25. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002; 21: 5716-5724.
26. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA 1998; 95: 4584-4588. (Pubitemid 28207956)
27. Greaves M. Pre-natal origins of childhood leukemia. Rev Clin Exp Hematol 2003; 7: 233-245. (Pubitemid 38076172)
28. Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002; 99: 8242-8247. (Pubitemid 34651037)
29. Trka J, Zuna J, Hrusak O, Kalinova M, Muzikova K, Lauschman H et al. Impact of TEL/AML1-positive patients on age distribution of childhood acute lymphoblastic leukemia in Czech Republic. Pediatric Hematology Working Group in Czech Republic. Leukemia 1998; 12: 996-997. (Pubitemid 28287227)
30. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764. (Pubitemid 46582031)
31. Bateman CM, Colman SM, Chaplin T, Young BD, Eden TO, Bhakta M et al. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood 2010; 115: 3553-3558.
32. Gefen N, Binder V, Zaliova M, Linka Y, Morrow M, Novosel A et al. Hsa-mir-125b-2 is highly expressed in childhood ETV6/ RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia 2010; 24: 89-96.
33. Schindler JW, Van Buren D, Foudi A, Krejci O, Qin J, Orkin SH et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell 2009; 5: 43-53.
34. Ford AM, Palmi C, Bueno C, Hong D, Cardus P, Knight D et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009; 119: 826-836.
35. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 2001; 21: 5577-5590. (Pubitemid 32702461)
36. Libermann TA, Pan Z, Akbarali Y, Hetherington CJ, Boltax J, Yergeau DA et al. AML1 (CBFalpha2) cooperates with B cellspecific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter. J Biol Chem 1999; 274: 24671-24676.
37. Pardali E, Xie XQ, Tsapogas P, Itoh S, Arvanitidis K, Heldin CH et al. Smad and AML proteins synergistically confer transforming growth factor beta1 responsiveness to human germ-line IgA genes. J Biol Chem 2000; 275: 3552-3560. (Pubitemid 30083064)